Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas Inc operates at the forefront of targeted protein degradation, a novel therapeutic approach that generates distinct news catalysts compared to traditional drug developers. The company's PROTAC platform, which induces complete protein degradation rather than temporary inhibition, produces news around clinical trial results, regulatory milestones, and scientific presentations that demonstrate this innovative mechanism in action.
News coverage for Arvinas typically centers on clinical data releases from its oncology programs, particularly trials evaluating protein degraders in hormone-dependent cancers. Each data readout provides insights into whether targeted protein degradation delivers on its theoretical advantages over conventional inhibitors, including deeper responses, longer durability, and activity in resistant disease. These clinical updates often include pharmacodynamic data confirming actual protein degradation in patients, a unique aspect of PROTAC development that validates the mechanism alongside efficacy measures.
Regulatory developments represent another key news category, including FDA interactions, clinical trial initiations, and submission milestones. For a company pioneering a new drug class, regulatory feedback shapes both individual program trajectories and the broader acceptance of protein degradation as a viable therapeutic modality. Scientific presentations at major oncology and drug discovery conferences also generate newsworthy content, as Arvinas shares preclinical data on pipeline expansion and mechanistic insights that inform the investment thesis around PROTAC technology.
Partnership announcements and collaborations provide additional news flow, signaling both industry validation of the platform and potential revenue streams. These deals often involve major pharmaceutical companies seeking to apply targeted protein degradation to their own proprietary targets, expanding the technology's reach beyond Arvinas' wholly-owned programs. Financial results and corporate developments round out the news landscape, offering insights into cash runway, program prioritization, and strategic direction as the company advances its clinical-stage pipeline toward potential commercialization.
Arvinas (NASDAQ: ARVN), a clinical-stage biotechnology company focused on developing targeted protein degradation drugs, has scheduled its first quarter 2025 financial results announcement and corporate update for Thursday, May 1, 2025, at 8:00 a.m. ET. The company will host a live webcast accessible through the 'Events and Presentations' section of their investor relations webpage. A recording of the webcast will be made available on www.arvinas.com after the event.
Arvinas (NASDAQ: ARVN) presented promising preclinical combination data for ARV-393, their PROTAC BCL6 degrader, at the 2025 AACR Annual Meeting. The study demonstrated significant antitumor activity in non-Hodgkin lymphoma models.
Key findings showed that ARV-393 combined with standard-of-care R-CHOP chemotherapy achieved complete tumor regressions in all treated mice. The drug also showed strong synergy when combined with biologics targeting CD20, CD19, or CD79b, and with small molecule inhibitors targeting BTK, BCL2, or EZH2.
Notably, ARV-393 increased CD20 expression, supporting its potential use with CD20-targeted therapies. A Phase 1 study (NCT06393738) is currently enrolling patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL.
Arvinas (NASDAQ: ARVN) announced that results from its Phase 3 VERITAC-2 clinical trial will be presented as a late-breaking oral presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will reveal the first pivotal data for vepdegestrant, a potential first-in-class oral PROTAC estrogen receptor degrader, being developed jointly with Pfizer.
The trial evaluated vepdegestrant versus fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The presentation, scheduled for May 31, 2025, will be delivered by Dr. Erika P. Hamilton from the Sarah Cannon Research Institute's Breast Cancer Research Program.
Arvinas (NASDAQ: ARVN) announced it will present new preclinical combination data for ARV-393, their investigational PROTAC BCL6 degrader, at the upcoming AACR Annual Meeting in Chicago (April 25-30, 2025). The presentation will focus on ARV-393's potential combination with standard lymphoma treatments.
The research highlights ARV-393, a PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), which is a transcriptional repressor and major driver of B-cell lymphomas. The poster presentation, titled 'ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models,' will be presented on April 28, 2025.
Arvinas (ARVN) presented promising first-in-human clinical trial data for ARV-102, their investigational oral PROTAC LRRK2 degrader, at AD/PD™ 2025. The trial demonstrated that ARV-102 successfully penetrates the blood-brain barrier and achieves substantial LRRK2 protein degradation in both central and peripheral systems.
Key findings showed ARV-102 was well-tolerated with no serious adverse events. At single doses ≥60mg and daily doses ≥20mg, the drug achieved >50% LRRK2 reduction in cerebrospinal fluid and >90% reduction in peripheral blood mononuclear cells. The Phase 1 trial included single ascending dose (SAD) cohorts (10-200mg) and multiple ascending dose (MAD) cohorts (10-80mg).
The company has initiated a Phase 1 trial in Parkinson's disease patients and expects to complete enrollment and present initial data from the SAD cohort, as well as initiate the MAD cohort, in 2025.
FAQ
What is the current stock price of Arvinas (ARVN)?
What is the market cap of Arvinas (ARVN)?
